Spero Therapeutics Inc logo

Spero Therapeutics Inc

NAS:SPRO (USA)  
$ 1.44 +0.02 (+1.41%) 02:46 PM EST
3.35
P/B:
0.71
Market Cap:
$ 77.61M
Enterprise V:
$ 5.74M
Volume:
126.52K
Avg Vol (2M):
389.54K
Also Trade In:
Volume:
126.52K
Avg Vol (2M):
389.54K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for SPRO ( Spero Therapeutics Inc ) from 2017 to Apr 25 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Spero Therapeutics stock (SPRO) PE ratio as of Apr 25 2024 is 3.35. More Details

Spero Therapeutics Inc (SPRO) PE Ratio (TTM) Chart

To

Spero Therapeutics Inc (SPRO) PE Ratio (TTM) Historical Data

Total 1215
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Spero Therapeutics PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-04-25 3.4 2024-02-21 3.5
2024-04-24 3.3 2024-02-20 3.6
2024-04-23 3.3 2024-02-16 3.6
2024-04-22 3.3 2024-02-15 3.5
2024-04-19 3.3 2024-02-14 3.4
2024-04-18 3.4 2024-02-13 3.4
2024-04-17 3.5 2024-02-12 3.5
2024-04-16 3.4 2024-02-09 3.2
2024-04-15 3.6 2024-02-08 3.1
2024-04-12 3.8 2024-02-07 3.4
2024-04-11 4.0 2024-02-06 3.4
2024-04-10 4.0 2024-02-05 3.4
2024-04-09 3.9 2024-02-02 3.4
2024-04-08 3.9 2024-02-01 3.6
2024-04-05 3.8 2024-01-31 3.5
2024-04-04 3.9 2024-01-30 3.6
2024-04-03 4.2 2024-01-29 3.7
2024-04-02 4.2 2024-01-26 3.6
2024-04-01 4.2 2024-01-25 3.6
2024-03-28 4.0 2024-01-24 3.6
2024-03-27 4.1 2024-01-23 3.5
2024-03-26 4.0 2024-01-22 3.4
2024-03-25 3.9 2024-01-19 3.2
2024-03-22 4.1 2024-01-18 3.3
2024-03-21 4.0 2024-01-17 3.4
2024-03-20 4.1 2024-01-16 3.4
2024-03-19 4.1 2024-01-12 3.4
2024-03-18 4.0 2024-01-11 3.4
2024-03-15 4.2 2024-01-10 3.5
2024-03-14 4.0 2024-01-09 3.4
2024-03-13 3.9 2024-01-08 3.3
2024-03-12 3.9 2024-01-05 3.3
2024-03-11 4.0 2024-01-04 3.4
2024-03-08 3.9 2024-01-03 3.4
2024-03-07 4.0 2024-01-02 3.5
2024-03-06 4.0 2023-12-29 3.4
2024-03-05 3.9 2023-12-28 3.4
2024-03-04 3.9 2023-12-27 140.0
2024-03-01 3.9 2023-12-26 145.0
2024-02-29 3.8 2023-12-22 135.0
2024-02-28 3.9 2023-12-21 136.0
2024-02-27 3.8 2023-12-20 135.0
2024-02-26 3.5 2023-12-19 138.0
2024-02-23 3.5 2023-12-18 130.0
2024-02-22 3.4 2023-12-15 129.0

Spero Therapeutics Inc (SPRO) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.